Back

AbNovoBench: a resource and benchmarking platform for monoclonal antibody de novo sequencing

Jiang, W.; Luo, L.; Xiong, Y.; Xiao, J.; Lin, Z.; Huang, L.; Zhang, S.; Wang, J.; Wang, C.; Xia, N.; Yuan, Q.; Yu, R.

2026-02-04 systems biology
10.64898/2026.02.02.703105 bioRxiv
Show abstract

Monoclonal antibodies (mAbs) are critical in disease diagnostics and therapeutics, yet the performance of mass spectrometry (MS)-based de novo sequencing remains incompletely characterized due to limited antibody-specific datasets and the absence of a standardized benchmark framework. Here we present AbNovoBench, a comprehensive framework for evaluating data analysis strategies for mAb de novo sequencing. It features the largest high-quality dataset to date, generated in-house, comprising 1,638,248 peptide-spectrum matches from 131 mAbs across six species and 11 proteases, supplemented by eight mAbs with known full-length sequence for end-to-end reconstruction assessment. Employing a unified training dataset, we systematically benchmarked 13 deep learning-based de novo peptide sequencing algorithms and three assembly strategies across peptide sequencing metrics (accuracy, robustness, efficiency, error types) and assembly metrics (coverage depth, assembly score). AbNovoBench (https://abnovobench.com) provides an online platform enriched with curated antibody MS resources and pre-trained models, enabling customizable antibody sequencing workflows, accelerating antibody-specific algorithms development, and improving reproducibility in proteomics.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.